Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Hipec (hyperthermic intraperitoneal chemotherapy)
What HIPEC is, how heated chemotherapy is delivered directly into the abdominal cavity after cytoreductive surgery, what the evidence says about survival in peritoneal cancers, who is a suitable candidate, approximate costs in Turkey compared with the UK, US and Germany, what recovery involves, realistic expectations and how to evaluate a centre offering this procedure.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for HIPEC (Hyperthermic Intraperitoneal Chemotherapy)
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is HIPEC and how does it work?
HIPEC (hyperthermic intraperitoneal chemotherapy) is a surgical oncology procedure that delivers heated chemotherapy drugs directly into the abdominal cavity at the end of an operation. It is always performed in combination with cytoreductive surgery (CRS) — a detailed operation to remove all visible tumour deposits from the peritoneum (the membrane lining the abdomen and covering the organs). Once the surgeon is satisfied that the visible disease has been cleared, a chemotherapy solution warmed to approximately 41–43 °C is circulated through the abdominal cavity for 60–90 minutes before being drained out. The heat makes cancer cells more sensitive to the drugs and helps the solution penetrate tissue more deeply, while keeping the exposure largely local and limiting the effect on the rest of the body. HIPEC is used for cancers that have spread to the peritoneum — including colorectal cancer, ovarian cancer, appendix cancer (pseudomyxoma peritonei) and mesothelioma — where systemic chemotherapy alone reaches the peritoneal surface poorly. For a broader overview of oncology treatments in Turkey, including systemic options, see our hub page.
What does the evidence say — does HIPEC work?
The evidence is strongest for certain diagnoses and weakest where disease is extensive. For appendix cancer (pseudomyxoma peritonei) and peritoneal mesothelioma, CRS combined with HIPEC is now the established standard of care at specialist centres, with five-year survival rates substantially higher than those seen with systemic chemotherapy alone in published series. For colorectal cancer with peritoneal metastases, a large Dutch randomised trial (PRODIGE 7, 2021) showed that adding HIPEC to complete CRS did not extend overall survival compared with CRS alone when oxaliplatin was used; however, subgroups and other drug regimens continue to be studied, and most specialist societies still recommend HIPEC in selected patients at high-volume centres. For ovarian cancer, HIPEC added to interval cytoreductive surgery showed a significant overall survival benefit in a 2018 New England Journal of Medicine trial (van Driel et al.), and it is increasingly incorporated into guidelines. What the evidence does not support is using HIPEC when cytoreduction is incomplete — residual bulky tumour substantially reduces any benefit — or when the patient cannot withstand a prolonged major operation. A specialist multidisciplinary team assessment is required before proceeding.
Who is — and who is not — a suitable candidate for HIPEC?
Patient selection is the most important factor in outcomes. Good candidates typically have peritoneal disease confined to the abdomen, a peritoneal cancer index (PCI) low enough for the surgeon to achieve complete or near-complete cytoreduction, adequate organ function (heart, lungs, kidneys, liver), acceptable nutritional status and a performance status that supports a major operation lasting six to twelve hours or more. A hospital with an established CRS/HIPEC programme will score the PCI on pre-operative imaging and sometimes with diagnostic laparoscopy before committing to open surgery.
Patients who are less suited include those with extensive disease beyond the peritoneum (liver parenchyma involvement, lung or bone metastases), very high PCI scores where complete cytoreduction is not achievable, significant cardiac or pulmonary disease, severely impaired kidney function (many HIPEC drugs are renally cleared), poor nutritional state or frailty. Age alone is not an exclusion, but physiological reserve matters. Patients should ask the team for a frank assessment of likely resectability before travelling.
The procedure step by step: cytoreductive surgery and HIPEC
The combined operation proceeds in several stages. First, general anaesthesia is established — this is a major abdominal procedure and always requires a general anaesthetic and an experienced anaesthetic team. The surgeon opens the abdomen and systematically inspects every surface, assigning a PCI score based on the size and distribution of tumour deposits. The cytoreductive phase then removes all visible tumour: this may include peritonectomy (stripping the peritoneal lining), removal of the omentum, bowel resection, spleen or other involved structures. Once the cytoreduction is complete and haemostasis achieved, the HIPEC phase begins: the abdomen may be left temporarily open (open technique) or closed (closed technique) while heated chemotherapy solution — typically oxaliplatin, cisplatin or mitomycin C depending on the cancer type — is pumped in, circulated for 60–90 minutes and then drained. The abdomen is irrigated and closed. Total theatre time commonly runs from six to twelve hours. Most patients spend one to three nights in intensive care before moving to a standard ward.
HIPEC cost in Turkey compared with the UK, US and Germany
HIPEC combined with cytoreductive surgery is one of the most resource-intensive procedures in oncology: it requires a specialist surgical team, an extended theatre slot, ICU support and a lengthy hospital stay. The figures below are approximate ranges; actual pricing depends on the extent of cytoreduction, duration in intensive care, length of stay, implants or stomas, and the chemotherapy agent used. Each hospital confirms its own price in a written treatment plan.
| Country | Approximate cost range (CRS + HIPEC) |
|---|---|
| Turkey | €12,000 – €30,000 |
| United Kingdom | €40,000 – €80,000 |
| United States | €50,000 – €120,000 |
| Germany | €35,000 – €75,000 |
What changes the price: the number of organs or peritoneal regions requiring resection (a straightforward omentectomy costs far less than multi-visceral resection), the chemotherapy drug used, ICU duration, total inpatient nights (commonly ten to twenty-one days in Turkey for international patients), imaging and pathology during the stay, and stoma reversal if applicable. A package at a Turkish centre for international patients typically includes pre-operative workup (CT, bloods, anaesthetic assessment), all surgery and anaesthesia fees, ICU and ward accommodation, chemotherapy drugs, medication during the stay, pathology and airport transfer. Confirm the full package list in writing, and ask specifically what is billed separately if complications extend the stay. For general information on how the process works when arranging treatment through our platform, see that guide.
HIPEC compared with its nearest alternatives
For peritoneal disease, HIPEC is not easily substituted — but the question most patients face is whether to proceed with CRS/HIPEC at all versus continuing systemic treatment or enrolling in a clinical trial. The table below summarises the realistic comparison.
| Approach | Best suited to | Typical limits |
|---|---|---|
| CRS + HIPEC | Confined peritoneal disease, complete cytoreduction achievable, fit patient | Major surgery risk; benefit reduced with high PCI or incomplete resection |
| Systemic chemotherapy alone | Extensive or unresectable disease; palliation; bridging to surgery | Poor peritoneal penetration; not curative for most peritoneal primaries |
| PIPAC (pressurised intraperitoneal aerosol chemotherapy) | Palliative setting; patients unfit for CRS; response assessment before CRS | Not combined with cytoreduction; evidence still maturing |
Some centres also offer targeted therapy or immunotherapy alongside or following HIPEC, depending on molecular tumour profiling. The multidisciplinary team at the treating centre should review all options and explain the rationale for the recommended sequence.
Recovery: what to expect week by week
Recovery from CRS and HIPEC is prolonged because two major interventions — a large abdominal operation and intraperitoneal chemotherapy — take place in a single session. Most patients should plan for the following milestones, which vary depending on the extent of surgery:
- Days 1–3: Intensive care monitoring for fluid balance, haemodynamic stability and organ function. Epidural or patient-controlled analgesia. Nasogastric tube and urinary catheter in place.
- Days 4–7: Transfer to ward when stable. Gradual reintroduction of oral fluids and diet as bowel function returns. Physiotherapy to prevent deep vein thrombosis.
- Days 8–14: Walking independently, tolerating a light diet. Wound checks. Many international patients remain in hospital for the full two weeks before travelling.
- Weeks 3–6: Fatigue is the dominant symptom. Light activity only. Wound healing. Some patients experience delayed bowel recovery or nausea from the chemotherapy agent.
- Weeks 6–12: Gradual return to normal activity. Follow-up imaging typically at three months. Return to work depends on the nature of the job — desk work from six to eight weeks; physical work later.
Most Turkish centres recommend a minimum stay of fourteen to twenty-one days for international patients before the surgical team permits travel. A video follow-up call after returning home allows the team to review healing and address early concerns. Systemic chemotherapy cycles, if planned post-operatively, usually begin six to eight weeks after HIPEC once recovery is confirmed.
Realistic results: what HIPEC can and cannot achieve
Survival data for CRS and HIPEC must be interpreted with the specific diagnosis and PCI in mind. For pseudomyxoma peritonei and peritoneal mesothelioma, long-term disease-free intervals of five or more years are reported in patients who achieve complete cytoreduction. For ovarian cancer, the 2018 NEJM trial showed a median overall survival of 45.7 months with HIPEC versus 33.9 months without. For colorectal peritoneal metastases, results depend heavily on completeness of resection and PCI score. No centre should promise a specific survival figure to an individual patient, because outcomes vary with tumour biology, molecular markers, the extent of disease and individual physiology. What photographs and case descriptions can honestly show is freedom from visible peritoneal disease on post-operative imaging and a return to normal or near-normal function in patients who recover well. Ask the centre for their own published or audited outcome data for your specific diagnosis, not for generic figures.
Risks and complications
CRS and HIPEC carries the risks of any major abdominal surgery plus those specific to intraperitoneal chemotherapy. Well-documented complications — reported in peer-reviewed literature and by organisations including the American Society of Colon and Rectal Surgeons (ASCRS) and NHS specialist commissioning reports — include:
- Surgical: anastomotic leak (if bowel is reconnected), bleeding, wound infection, hernia, ileus (delayed return of bowel function) and injury to surrounding structures.
- Chemotherapy-related: bone marrow suppression (low blood counts), kidney impairment (particularly with cisplatin), peripheral neuropathy and nausea.
- General: deep vein thrombosis, pulmonary embolism, pneumonia and, rarely, death. Mortality rates at high-volume specialist centres in published series are typically quoted at 1–4%; morbidity rates are substantially higher, with major complications in 20–40% of patients depending on case complexity.
The risk profile is the main reason patient selection and centre volume matter: centres performing fewer than a handful of these procedures per year have higher complication and mortality rates in published comparative studies. Ask the centre how many CRS/HIPEC procedures they perform each year and what their major complication rate is.
How to choose a centre and what red flags to watch for
HIPEC is a highly specialised procedure and should only be carried out at a centre with a dedicated surgical oncology team experienced in both cytoreductive surgery and intraperitoneal chemotherapy. When evaluating a Turkish or any other centre, check the following:
- The operating surgeon is a specialist in surgical oncology or colorectal/gynaecological oncology with specific HIPEC training, not a general surgeon who performs it occasionally.
- The centre has a multidisciplinary tumour board that reviews HIPEC cases before surgery.
- An intensive care unit is on site and the ICU team is experienced in post-HIPEC patients.
- The centre can provide their own outcome data (number of cases per year, mortality rate, major complication rate) for your diagnosis.
- You receive a written treatment plan — including PCI assessment, proposed cytoreduction, chemotherapy agent, expected hospital stay and total cost — before you pay any deposit.
Red flags include centres that cannot provide outcome data for your specific diagnosis, that quote without reviewing your imaging, that pressure you to decide quickly or that promise cure or a specific survival duration. Read how our process works and request a free quote: the hospital reviews your records and sends a written plan. For more on the range of oncology treatments in Turkey available through our platform, see the hub page.
- How many CRS/HIPEC procedures does your team perform each year for my diagnosis?
- What is your centre's major complication and mortality rate for this operation?
- Will my case be reviewed by a multidisciplinary tumour board before the operation?
- What is the plan if cytoreduction turns out to be incomplete once inside?
- Which chemotherapy agent will you use and why?
- What is included in the quoted price and what could cause the final bill to be higher?
- How will post-operative systemic chemotherapy be coordinated with my oncologist at home?
Hospitals with Oncology in Turkey
Frequently asked questions
HIPEC (hyperthermic intraperitoneal chemotherapy) is a procedure in which heated chemotherapy solution is circulated inside the abdominal cavity at the end of cytoreductive surgery. The heat makes cancer cells more sensitive to the drugs and improves penetration into tissue, while limiting systemic side-effects.
Evidence is strongest for appendix cancer (pseudomyxoma peritonei), peritoneal mesothelioma and ovarian cancer, where CRS and HIPEC can significantly extend survival compared with chemotherapy alone. For colorectal peritoneal metastases, benefit depends on achieving complete cytoreduction. HIPEC is not effective when large volumes of tumour remain after surgery.
Approximate ranges for the combined cytoreductive surgery and HIPEC procedure are €12,000 to €30,000 in Turkey, compared with €40,000 to €80,000 in the UK. The final figure depends on the extent of surgery, ICU stay, length of hospitalisation and the chemotherapy agent used.
Recovery is prolonged. Most patients spend one to three nights in intensive care and ten to twenty-one days in hospital in total. Fatigue and reduced appetite continue for several weeks. A return to desk work is realistic at six to eight weeks; physical work takes longer. International patients should plan to stay in Turkey for at least fourteen days.
Good candidates have peritoneal disease that is confined to the abdomen, a peritoneal cancer index low enough for complete cytoreduction, adequate organ function and fitness for a major operation. Patients with disease spread beyond the peritoneum, very extensive peritoneal involvement or significant co-morbidities are generally not suitable.
The operation is performed under general anaesthesia. Post-operatively, pain is managed with epidural analgesia or patient-controlled analgesia. The first days are uncomfortable, and fatigue and discomfort from the chemotherapy agent can persist for several weeks, but most patients report that pain is manageable with the medications provided.
Survival varies by diagnosis and the completeness of cytoreduction. For pseudomyxoma peritonei and peritoneal mesothelioma, five-year survival rates in specialist centres can exceed 50%. For ovarian cancer, the 2018 NEJM trial reported improved median survival. Centres should provide their own audited data for your specific diagnosis rather than generic figures.
Risks include anastomotic leak, infection, bleeding, delayed bowel recovery, kidney impairment and bone marrow suppression. Major complication rates at specialist centres are reported in the range of 20–40% depending on case complexity; mortality at high-volume centres is typically 1–4%. The risks are substantially lower at centres performing large numbers of these procedures.
Systemic chemotherapy penetrates the peritoneal surface poorly and is not curative for most peritoneal primaries. HIPEC delivers a high local concentration directly to the peritoneum. It is not a replacement for systemic treatment — post-operative chemotherapy is often still recommended — but it adds a local treatment dimension that systemic drugs cannot provide.
Plan for a minimum of fourteen to twenty-one days in Turkey. The hospital stay itself is typically ten to twenty-one days depending on the extent of surgery and your recovery. The surgical team will confirm when it is safe to fly; for a procedure of this complexity, an earlier discharge is rarely appropriate for international patients.
Patient stories